Cinical utility of measuring biologics and human anti-chimeric antibody concentrations in patients with IBD

Cinical utility of measuring biologics and human anti-chimeric antibody concentrations in patients with IBD - Cinical utility of measuring biologics and human anti-chimeric antibody concentrations in patients with IBD

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000005611

Enrollment

100

Registered

2011-05-17

Start date

2011-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ulcerative colitis, Crohn&#39

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who use biologics

Exclusion criteria

Exclusion criteria: Patients without biologics

Design outcomes

Primary

Measure	Time frame
Comparison of infliximab concentration and anti-chimeric antibody in patients on remission with those in patients on clinically active	—

Countries

Japan

Outcome results